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Abstract Production of considerable amounts of reactive
oxygen species (ROS) eventually leads to oxidative stress.
A key role of oxidative stress is evident in the pathologic
mechanisms of endothelial dysfunction and associated
cardiovascular diseases. Vascular enzymes such as NADPH
oxidases, xanthine oxidase, and uncoupled endothelial
nitric oxide synthase are involved in the production of
ROS. The question remains whether pharmacologic
approaches can effectively combat the excessive ROS
production in the vasculature. Interestingly, existing regis-
tered cardiovascular drugs can directly or indirectly act as
antioxidants, thereby preventing the damaging effects of
ROS. Moreover, new compounds targeting NADPH oxi-
dases have been developed. Finally, food-derived com-
pounds appear to be effective inhibitors of oxidative stress
and preserve vascular function.
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Introduction
Aerobic life is inconceivable without oxygen, yet oxygen is
the major factor that makes life finite. Vascular (dys)
function is an illustrative example of the manifestation of
oxygen’s mixed blessing on the organ level. During the past
decade, a large body of evidence identified oxygen reaction
products, the so-called reactive oxygen species (ROS), as
important molecules in signal transmission and regulation
of vascular function. However, excessive ROS production
leads to oxidative stress, which has been determined to play
a key role in the pathophysiology of cardiovascular diseases
such as endothelial dysfunction, atherosclerosis, hyperten-
sion, and myocardial infarction. This article provides an
overview of the main molecular sources of ROS in the
vessel wall contributing to the development of oxidative
stress and associated impaired vascular function. In
addition, this review discusses the availability and potential
of antioxidant treatment strategies by focusing on well-
established cardiovascular drugs as well as on dietary
compounds and the latest drug developments specifically
designed to target ROS overproduction (Fig. 1).
ROS in Vascular (Dys)function
ROS are generated during the reduction of oxygen and
comprise two groups of molecules: 1) free radicals with
short biological half-lives, such as superoxide (O2
•−),
hydroxyl (OH•), and nitric oxide (•NO), and 2) nonradicals,
such as singlet oxygen (1O2), hydrogen peroxide (H2O2),
hypochlorous acid (HOCl), peroxynitrite (ONOO−), and
lipid hydroperoxides (LOOH), which are more stable and
have longer half-lives than free radicals. Cellular ROS
formation is a physiologic process in the vasculature and
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occurs in endothelial and smooth muscle cells as well as
fibroblasts. Although ROS are small, structurally simple
molecules with high and random reactivity, they appear to
be subtle physiologic modulators of biochemical processes
involved in intracellular signaling [1]. Signal transmission
via ROS takes place at free sulfhydryl groups of cysteine
residues, which are present in many enzymes, including
kinases (eg, Src, Akt, protein kinase C [PKC], mitogen-
activated protein kinases [MAPKs], and Rho kinases),
phosphatases (eg, protein tyrosine phosphatases, SH2
domain-containing phosphatases, MAPK phosphatase),
phospholipases (eg, phospholipase A2), and small GTPases
(eg, Rac1, RhoA), as well as transcription factors (see later)
and ion channels (eg, Ca2+ and K+ channels). The ROS-
induced oxidation of sulfhydryl groups leads to intra- and
intermolecular disulfide bonds. This posttranslationally
alters the conformation of proteins, eventually resulting in
altered enzyme activity or DNA binding. Among the
Fig. 1 Molecular sources of vascular oxidative stress and pharmaco-
logic intervention strategies. Vascular enzymes such as NADPH
oxidase 2 (1), xanthine oxidase (2), and uncoupled endothelial nitric
oxide synthase (3) can promote the production of reactive oxygen
species (ROS) considerably. Eventually, these processes contribute
to the development of endothelial dysfunction and vascular damage.
Established and novel cardiovascular drugs, as well as dietary
flavonoids, can attenuate cellular ROS concentrations via direct or
indirect mechanisms. ACE—angiotensin-converting enzyme; Ang—
angiotensin; AT1—Ang II type 1; CaM—calmodulin; ET-1—
endothelin 1; FAD—flavin adenine dinucleotide; FMN—flavin
mononucleotide; L-Arg—L-arginine; L-Cit—L-citrulline; PDGF—
platelet-derived growth factor; TGF-β—transforming growth factor-β
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complex protein networks transmitting information from
the cell surface to the nucleus, several transcription factors
(eg, nuclear factor-κB [NF-κB]/Rel family, activator protein
1, hypoxia-inducible factors 1 and 2, p53, c-myc, metal-
responsive transcription factor) were first discovered to
become activated or inhibited by exogenous and/or ligand-
induced oxidants. In the meantime, it is known that the
signal propagation upon receptor binding of growth factors
such as platelet-derived growth factor (PDGF), epidermal
growth factor, nerve-derived growth factor, and endothelin
(ET)-1, as well as cytokines such as tumor necrosis factor
(TNF)-α and interleukin (IL)-1β, is mediated via the
generation of O2
•− and H2O2. Notably, the activation of G
protein-coupled receptors such as β-adrenergic receptors
and angiotensin (Ang) II type 1 (AT1) receptors by
particular agonists results in the production of ROS and/or
•NO, which act as signaling molecules in the receptor-
mediated regulation of gene expression and cell growth
[2•]. To prevent potentially damaging actions and maintain
cellular redox balance, enzymatic antioxidant defense
systems, including catalase, superoxide dismutase, glutathi-
one peroxidase, and thioredoxin, detoxify and remove
ROS. However, when the balance between ROS production
and scavenging becomes disturbed, oxidative stress occurs.
In this state of excessive ROS production, the ROS-
stimulated signaling process switches to a ROS-mediated
decrease in bioavailable •NO and damage to lipids,
proteins, and DNA. As a consequence, uncontrolled cellular
proliferation, apoptosis, increased cellular permeability, and
cell death may occur, which in turn leads to endothelial
dysfunction, inflammation, and vascular remodeling. All
these events are crucial contributors to cardiovascular
disease pathologies.
Sources of ROS in the Vasculature
When prolonged ROS accumulation emerges in a dysregu-
lated vascular redox environment, next to mitochondrial
respiration, three enzymes have been identified as major
sources of ROS: NAD(P)H oxidases (NOX), xanthine
oxidase (XO), and uncoupled endothelial nitric oxide
synthase (eNOS).
NAD(P)H Oxidases
Initially, NADPH oxidases were thought to be enzymes
present only in phagocytes of the innate immune response,
where they are responsible for generating large amounts of
O2
•− to kill invading pathogens (“oxidative burst”). Upon
activation, O2 is reduced to O2
•− by the transfer of one
electron from the reducing equivalent NADH or NADPH.
However, these enzymes that exist only to produce free
radicals appeared unexpectedly in nonphagocytic cells, and
it became evident in the past 10–15 years that NADPH
oxidases exist in various cell types. In the course of these
discoveries, a new terminology was introduced designating
nonphagocytic NADPH oxidases as the NOX family. Our
current knowledge of the physiologic and pathophysiologic
roles of this enzyme family in general and in the
cardiovascular system in particular is compiled in several
excellent reviews [3••, 4, 5••, 6, 7].
In brief, NOX family NADPH oxidases comprise seven
isoforms: NOX1, NOX2 (formerly gp91phox), NOX3,
NOX4, NOX5, and dual oxidases 1 and 2 (DUOX1 and
DUOX2). All isoforms are transmembrane proteins and
consist of multiple subunits located in both the cytosol
and the cellular membrane. When the cytosolic subunits
p40phox, p47phox, p67phox, the small GTPase Rac, and
NOXO1 and NOXA1 are assembled with the two
membrane-bound units, gp91phox (NOX2) and p22phox,
the protein is fully functional and transports electrons
across the membrane to reduce O2 to O2
•−.
The transmembranous enzyme complex is located in the
membrane so that the NADPH binding domain lies in the
cytoplasm, whereas the O2
•−-generating part is situated in
either the extracellular or the intraorganellar space. Inter-
estingly, the membrane-bound catalytic subunits gp91phox
and p22phox, which together form the heterodimeric
flavocytochrome b558, already contain the complete cata-
lytic machinery for the electron transfer from NADPH to
O2, and a basal, albeit low, production of superoxide
radicals has been observed even in the absence of NOX
stimulators. The cytosolic subunits have regulatory func-
tions related to organization (p47phox and NOXO1),
activation (p67phox and NOXA1), and, specifically in the
case of DUOX, maturation (DUOXA1 and DUOXA2).
Previous insights into the NOX family revealed obvious
structural and functional differences among NOX isoforms
as well as distinct regulatory mechanisms and distribution in
cells and organs [3••]. In vascular endothelial cells, NOX 4,
in addition to NOX2 and NOX5, is abundant, whereas in
smooth muscle cells, both NOX1 and NOX4 predominate.
In adventitial fibroblasts, NOX 4 prevails and in macro-
phages, NOX2. The O2
•− radicals generated by these cells in
the vascular wall readily react with •NO, considerably
lowering its vasorelaxant effect.
The activity of NADPH oxidases is stimulated particularly
by Ang II but also by other vasoactive hormones (eg, ET-1),
growth factors (eg, PDGF, transforming growth factor-β), and
mechanical stimuli (shear stress and stretch).
Although it remains to be elucidated how the different
NOX isoforms are precisely regulated and interact in
vascular cells, their ROS production unmistakably contributes
to cardiovascular pathologies as endothelial dysfunction,
atherosclerosis, and hypertension.
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Xanthine Oxidase
XO and xanthine dehydrogenase (XDH) are both xanthine
oxidoreductases (XORs), a group of enzymes known as
molybdenum iron-sulfur flavin hydroxylases. Historically,
they were considered two distinct enzymes, although it
could be demonstrated that both enzymes are encoded by
the same gene and are interconverted either reversibly or
irreversibly in vivo [8]. XORs catalyze the oxidation of
hypoxanthine to xanthine and xanthine to uric acid. For
these reactions, XDH prefers NAD+ and XO uses O2 as an
electron acceptor, thereby producing NADH and O2
•− and
H2O2, respectively. The protein structure of the active XOR
consists of a homodimer in which each subunit harbors a
molybdopterin moiety, two Fe2–S2 centers, and flavin
adenine dinucleotide (FAD) as cofactors. Oxidation of a
substrate takes place at the molybdenum center, from which
the accepted electrons are transported rapidly via the Fe2–
S2 centers to FAD, which in turn reduces the oxidant
substrate NAD+ or O2 [9, 10]. Notably, reoxidation of a
fully reduced XO occurs stepwise and comprises the
transfer of six electrons to O2, yielding two molecules of
H2O2 and two molecules of O2
•−. Next to hypoxanthine and
xanthine, XOR also can hydrolyze a wide array of
aldehydes and N-heterocyclic substrates, thereby contribut-
ing to the activation and/or detoxification of endogenous or
xenobiotic compounds. Moreover, it exhibits nitrate and
nitrite reductase activity, which generates •NO, particularly
in hypoxic conditions in which eNOS is not able to produce
•NO.
XORs are distributed widely in the human body, with
high levels in the gut and liver. Their expression and
activity are regulated on both the transcriptional and
posttranslational level. For example, proinflammatory stim-
uli (eg, lipopolysaccharide, TNF-α, IL-1, and IL-6) and
hypoxia can significantly upregulate the transcription of
XO. Furthermore, a variety of patients with cardiovascular
disease (e.g., coronary artery disease, heart failure, and
hypertension) reveal significantly elevated XO levels.
Interestingly, there is a circulating form of XO that can
bind to glycosaminoglycans on the surface of endothelial
cells and may acquire increased stability and oxidant-
producing capacity upon binding [11]. In patients with
chronic heart failure, the activity of this endothelial-bound
XO increases by more than 200% [12]. Consequently, high
amounts of O2
•− are produced that may quickly react with
•NO released from endothelial cells to form cytotoxic
ONOO−. Evidence suggests that the formation of ONOO−
and the activation of downstream signaling pathways
finally result in endothelial cell injury [11, 13]. In those
pathophysiologic conditions, the use of XO inhibitors may
be a reasonable targeted antioxidant approach.
Uncoupled Endothelial Nitric Oxide Synthase
eNOS is a homodimer consisting of two monomers that
each contain a reductase domain capable of binding
NADPH, FAD, and flavin mononucleotide (FMN) and an
oxygenase domain that carries a prosthetic heme group.
These heme groups are necessary for the dimerization of
both monomers to form the active NOS dimer and for the
electron transfer from the flavin to the heme of the opposite
monomer. To become a fully operational enzyme complex,
the oxygenase domain binds (6R)-5,6,7,8-tetrahydrobiop-
terin (BH4), molecular oxygen, and the substrate L-arginine.
Finally, a zinc ion binds at the interfaces of the NOS dimer,
which has mainly a structural function [14]. eNOS
catalyzes an electron transfer within the reductase domain
from NADPH via the flavins FAD and FMN to the heme in
the oxygenase domain. Calcium-induced binding of cal-
modulin to the reductase domain increases this electron
transfer. At the heme of the oxygenase domain, O2 is
reduced and L-arginine is oxidized in two steps via N-
hydroxy-L-arginine to L-citrulline and •NO. eNOS activity
is regulated by the intracellular calcium concentration and
phosphorylation in the reductase and calmodulin-binding
domain. Depending on the stimulus, several kinases can
phosphorylate eNOS, including Akt/protein kinase B,
protein kinase A, 5′-adenosine monophosphate-activated
protein kinase, and calmodulin-dependent kinase II.
If the electron flow becomes disturbed within eNOS (in
vitro this may occur because of the absence of the cofactor
BH4 or the substrate L-arginine), O2
•− will be generated
from the oxygenase by dissociation of the ferrous-dioxygen
complex. This state of eNOS uncoupling has been observed
not only experimentally, but also in humans with essential
hypertension [15] or hypercholesterolemia-associated en-
dothelial dysfunction [16] and in chronic smokers [17].
Several molecular triggers have been identified that likely
contribute to eNOS uncoupling in vivo. During normal
catalytic function of eNOS, BH4 acts as an electron donor.
Its oxidized form can be recycled to BH4 by the enzyme
itself. However, in an environment of increased O2
•−
production—as a result, for example, of elevated NOX
and/or XO activity—O2
•− can react with eNOS formed •NO
to the highly reactive ONOO−. ONOO− has been shown to
oxidize BH4 to biologically inactive products that cannot
be recycled further. Eventually, this results in an
uncoupling of eNOS. This phenomenon also is observed
when L-arginine levels fall below those required to
saturate eNOS. Because the Km of eNOS for L-arginine
lies between 1 and 10 µM and intracellular L-arginine
concentrations are up to 10 times higher than plasma
concentrations (approximately 80–120 µM), it appears
unlikely that L-arginine might become a limiting factor in
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vivo [18]. However, there is evidence from hypertensive
humans that augmented activity and/or expression of the
L-arginine catabolizing enzyme arginase may be responsi-
ble for locally diminished L-arginine concentrations [19].
Finally, there is indication that the endogenous eNOS
inhibitor asymmetric dimethyl-L-arginine can uncouple
eNOS, because it competitively displaces L-arginine from
its eNOS binding site [20].
Pharmacologic Interventions in Vascular
Oxidative Stress
Registered Cardiovascular Drugs with Direct
Antioxidant Activity
The current awareness that oxidative stress plays a pivotal
role in the pathophysiologic processes of vascular dysfunc-
tion resulted in several treatment strategies to alter ROS
levels by decreasing production and/or increasing radical
scavenging. In that respect, it is interesting to note that part
of the pharmacologic activity of long-established cardio-
vascular drugs might be a result of their antioxidant
properties. For example, it has been shown that antiar-
rhythmic drugs can inhibit lipid peroxidation [21]. Also,
several β-blockers dose-dependently inhibit membrane
lipid peroxidation [22]. The β-blocker carvedilol contains
a β- and α1-adrenoceptor-blocking pharmacophore as well
as a specific carbazole moiety to enhance its antioxidant
activity. Also, the metabolites of carvedilol are active
antioxidants [23, 24].
By comparing the various classes of Ca2+ antagonists,
studies showed that the dihydropyridines (eg, nifedipine,
nisoldipine) were particularly effective in protecting against
H2O2-induced decreases in contractile function of rat hearts
[25] and low-density lipoprotein oxidation [26].
Registered Cardiovascular Drugs with Indirect
Antioxidant Activity
The antioxidant activity of angiotensin-converting enzyme
(ACE) inhibitors, especially the sulfhydryl group contain-
ing captopril, has been discussed extensively [27]. It also
was suggested that enalapril and captopril might indirectly
enhance the tissue antioxidant defense mechanisms [28].
The in vivo relevance of the direct systemic antiradical
effects, however, have been strongly disputed [29]. Indeed,
the general antioxidant (radical scavenging) action of drugs
is not likely to be very effective clinically. The concen-
trations needed are probably too high to reach. Thus, the
putative antioxidant action of ACE inhibitors might be
displayed in a more confined tissue area. Ang II potently
stimulates NADPH oxidases in various cells of the
vasculature, promoting the generation of O2
•− [30]. ACE
inhibition thus limits the formation of O2
•− [31]. A similar
indirect antioxidant effect may be expected from the Ang II
receptor blockers, the “sartans.”
Similarly, part of the pleiotropic effect of statins has been
explained by an indirect antioxidant mechanism, in this
case by their inhibitory effect on the coupling of the AT1
receptor to the NADPH oxidase [32].
If source-directed inhibition of ROS generation improves
vascular function, XO inhibition also should have a
beneficial effect. Indeed, a recent review describes encour-
aging results for the XO inhibitor allopurinol [33••].
Newly Designed Antioxidant Drugs
Specific medical-chemical approaches have been used to
design antioxidant drugs for the vascular system. In the late
1980s, the so-called 21-aminosteroids were designed to
protect against acute and delayed vascular consequences
after a subarachnoid hemorrhage [34].
Based on the antioxidant chromanol moiety of vitamin E
(α-tocopherol), quaternary ammonium analogues of α-
tocopherol were developed and have been proven to
successfully decrease the heart infarct size in animals
[35]. Many other antioxidant hybrid molecules have been
designed, and this line of research continues. Losartan-
antioxidant hybrids [36•], antiarrhythmic-α-tocopherol hybrids
[37], and troglitazone, an α-tocopherol-thiazolidinedione
hybrid that is a peroxisome proliferator-activated receptor-γ
ligand with antioxidant activity are examples in this regard.
The clinical application of the latter was discontinued because
of hepatotoxicity [38].
New peptide inhibitors have been developed to specif-
ically target NADPH oxidases [5••]. The 18-amino acid
peptide gp91ds-tat interferes with NADPH oxidase and
subunit assembly and attenuates vascular O2
•− production.
Nine of its amino acids mimic the region of p22phox that
interacts with p47phox.
PR39 is a naturally occurring 39-amino acid proline- and
arginine-rich peptide originally isolated from pig intestine.
PR39 binds to the Src homology domain 3 (SH3) p47phox
and, like gp91ds-tat, prevents the association between
p47phox and NOX proteins.
A specific NADPH oxidase inhibitor, VAS2870, was
found recently and is awaiting further characterization.
The frequently used NADPH inhibitor apocynin is a
methoxy-catechol extracted from the Picroria kurroa plant
and oxidized by intracellular peroxidases into active
metabolites. Moreover, nitration and nitrosylation of the
NADPH oxidase lead to inhibition of the enzyme. In
addition, PKC plays an important role in the activation of
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NADPH oxidase through phosphorylation of p47phox. In
this way, PKC inhibitors also decrease O2
•− production by
the NADPH oxidase.
As mentioned, with a shortage of BH4, NOS uncouples
and produces O2
•− rather than •NO. However, supplemen-




The cardiotoxicity of doxorubicin, a generally used agent
for heart failure, can be prevented with antioxidants. The
flavonoid 7-monohydroxyethylrutoside effectively protects
against doxorubicin-induced toxicity [39]. Interestingly, this
flavonoid effectively protects against the neutrophil infil-
tration of ischemic heart tissue in mice after reperfusion
[40].
Recently, the antioxidant and anti-inflammatory action
of flavonoids was explored in more detail. It has been
suggested that in the inhibition of the proinflammatory
transcription factor NF-κB by the flavonoids, attenuating
effects on poly(ADP-ribose) polymerase are involved
[41].
Because flavonoids are a substantial part of fruits and
vegetables, it is tempting to suggest that these polyphenols
contribute to their cardiovascular effects. In fact, a high
intake of fruits and vegetables has been associated with a
decrease in blood pressure in humans [42]. The endothelial-
protective effects of flavonoids may be related to other
activities of these compounds, such as inhibition of ET-1
synthesis [43] or inhibition of arginase [44], increasing the
availability of L-arginine, which forms the rate-limiting
factor for cellular •NO production. It has further been
proposed that the prevailing mode of action of flavonoids is
inhibition of NADPH oxidase, thus lowering the O2
•−
generation that leads to elevation of •NO levels in the cell.
The long-term effect of flavonoids is probably mediated by
alterations in gene expression and protein synthesis, such as
eNOS [45].
It will be interesting to investigate whether the hereto-
fore unsolved mechanism of the antihypertensive effect
of a tomato extract, which is observed even when the
extract is administered on top of regular pharmacologic
treatment in humans, also differs with regard to short-
term and long-term administration. Paste from genetically
modified tomatoes enriched in quercetin inhibited the
development of hypertension in spontaneously hyperten-
sive rats [46].
Polyphenols and their metabolites probably preserve the
•NO/O2
•− balance by inhibition of NADPH oxidase
combined with O2
•− scavenging. From that view, poly-
phenols differ from the antioxidant vitamins ascorbic acid
and α-tocopherol, which increase the efficacy of eNOS by
ensuring the level of the cofactor BH4 [47].
Conclusions
Several already-registered cardiovascular-effective com-
pounds possess prominent antioxidant activity, which may
explain some of their therapeutic activity. Changes in
cellular redox status with antioxidant vitamins also may
improve •NO availability, either by supporting the eNOS
cofactor BH4 level or by decreasing the O2
•−-mediated
abolition of •NO. More promising is the inhibition of the
vascular O2
•−-generating NADPH oxidase. It appears that
here, too, established, successful drugs possess this inhib-
itory effect. Moreover, vasoactive food-derived flavonoids
exhibit this effect in addition to their well-known antiox-
idant action.
Our increasing knowledge of the molecular sources of
oxidative stress and its role in vascular function will enable
the development of new vasoactive pharmacologic and
dietary modulators of the pathogenesis of cardiovascular
disease.
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